Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer

靶向磷脂酰丝氨酸/TAM 受体/PD-L1 轴作为癌症的脆弱性

基本信息

  • 批准号:
    10365623
  • 负责人:
  • 金额:
    $ 50.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-01 至 2023-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary: Tyro3, Axl, and Mertk (abbreviated TAM receptors) are a family of homologous type I Receptor Tyrosine Kinases (RTKs) that have homeostatic functions under physiological conditions to dampen inflammation and maintain tissue tolerance in multi-cellular organisms. The ligands for TAMs are two vitamin K- modified proteins, Growth arrest specific factor 6 (Gas6) and Protein S (Pros1) that bind phosphatidylserine (PS) on apoptotic cells, and in doing so, act as bridging molecules to facilitate the clearance of apoptotic cells (efferocytosis). While PS-mediated efferocytosis, most emblematically via Mertk expressed on macrophages, have important homeostatic functions to prevent chronic inflammation and autoimmunity, the constitutively externalized PS that occurs in the tumor microenvironment (TME) of solid cancers, in combination with the expression of Mertk on infiltrating macrophages, patho-physiologically subvert PS- mediated tolerogenic functions to suppress host anti- tumor immune responses. The central hypothesis in this application is that constitutively dys- regulated PS externalization observed in the TME, in combination with the infiltration of Mertk-expressing macrophages, act as an important immune inhibitory axis to suppress host anti- tumor immunity. This axis is likely to be activated in a wide range of solid cancers for immune escape, but also may represent vulnerability in cancer if effectively targeted by therapeutics. In this application, we outline mechanistic experiments to identify how externalized PS is dysregulated in the TME (aim #1) as well as determine the mechanisms by which Mertk acts as an inhibitory receptor on macrophages to suppress host anti-tumor immunity and tolerance (aim #2). In aim #3, we propose a series of pre-clinical therapeutic mouse studies to test combinations of a first- in-class anti-Mertk neutralizing mAb in combination with anti-PD1 mAb, as well as explore and validate the biology of Mertk as an inhibitory receptor using human models. Collectively, our studies aim to open up new avenues to interrogate a novel type of checkpoint inhibitory network in immuno-oncology.
项目总结: Tyro3、Ax1和MerTK(缩写为受体)是一个同源的I型受体家族 在生理条件下具有动态平衡功能的酪氨酸激酶(RTK) 在多细胞生物体中抑制炎症和维持组织耐受性。的配基 TAMs是两种维生素K修饰的蛋白质,生长停滞特异性因子6(Gas6)和蛋白质S (Pros1)与凋亡细胞上的磷脂酰丝氨酸(PS)结合,并在此过程中起到桥接的作用 有助于清除凋亡细胞的分子(胞泡吞噬)。而PS介导的 巨噬细胞上表达的MerTK最具代表性的吞噬作用具有重要的作用 体内平衡功能,以防止慢性炎症和自身免疫,构成 出现在实体癌肿瘤微环境(TME)中的外部性PS 通过MerTK在浸润性巨噬细胞上的表达,病理生理上颠覆PS- 介导的致耐受功能抑制宿主抗肿瘤免疫反应。中环 这个应用中的假设是,结构性的dys调节的PS外化 在TME中观察到,结合MerTK表达的渗透 巨噬细胞是抑制宿主抗肿瘤的重要免疫抑制轴 豁免权。这个轴很可能在广泛的实体癌症中被激活,以进行免疫逃避, 但如果有效地被治疗学靶向,也可能代表癌症的脆弱性。在这 应用,我们概述了机制实验,以确定外部化的PS是如何失调的 在TME中(目标1),以及确定MerTK作为抑制物的机制 巨噬细胞上的受体抑制宿主抗肿瘤免疫和耐受性(目标2)。在AIM #3,我们提出了一系列临床前治疗性小鼠研究,以测试第一个- 类内抗MerTK中和单抗与抗PD1单抗的结合,以及探索和 利用人体模型验证MerTK作为抑制性受体的生物学特性。总的来说,我们的 研究旨在开辟新的途径来询问一种新型的检查点抑制网络 在免疫肿瘤学方面。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAYMOND B BIRGE其他文献

RAYMOND B BIRGE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAYMOND B BIRGE', 18)}}的其他基金

Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer
靶向磷脂酰丝氨酸/TAM 受体/PD-L1 轴作为癌症的脆弱性
  • 批准号:
    10554443
  • 财政年份:
    2022
  • 资助金额:
    $ 50.82万
  • 项目类别:
Non-canonical signal pathway for Crk in breast cancer
乳腺癌中 Crk 的非经典信号通路
  • 批准号:
    8701004
  • 财政年份:
    2012
  • 资助金额:
    $ 50.82万
  • 项目类别:
Non-canonical signal pathway for Crk in breast cancer
乳腺癌中 Crk 的非经典信号通路
  • 批准号:
    8402232
  • 财政年份:
    2012
  • 资助金额:
    $ 50.82万
  • 项目类别:
Non-canonical signal pathway for Crk in breast cancer
乳腺癌中 Crk 的非经典信号通路
  • 批准号:
    9246662
  • 财政年份:
    2012
  • 资助金额:
    $ 50.82万
  • 项目类别:
Non-canonical signal pathway for Crk in breast cancer
乳腺癌中 Crk 的非经典信号通路
  • 批准号:
    8509636
  • 财政年份:
    2012
  • 资助金额:
    $ 50.82万
  • 项目类别:
Targeting FKBP52 and Copper in Alzheimer's Disease
靶向 FKBP52 和铜治疗阿尔茨海默病
  • 批准号:
    7150136
  • 财政年份:
    2006
  • 资助金额:
    $ 50.82万
  • 项目类别:
Targeting FKBP52 and Copper in Alzheimer's Disease
靶向 FKBP52 和铜治疗阿尔茨海默病
  • 批准号:
    7270115
  • 财政年份:
    2006
  • 资助金额:
    $ 50.82万
  • 项目类别:
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF
NGF 新型信号通路的鉴定
  • 批准号:
    6342942
  • 财政年份:
    1999
  • 资助金额:
    $ 50.82万
  • 项目类别:
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF
NGF 新型信号通路的鉴定
  • 批准号:
    6331057
  • 财政年份:
    1999
  • 资助金额:
    $ 50.82万
  • 项目类别:
IDENTIFICATION OF A NOVEL SIGNAL PATHWAY FOR NGF
NGF 新型信号通路的鉴定
  • 批准号:
    2758467
  • 财政年份:
    1999
  • 资助金额:
    $ 50.82万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 50.82万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了